Daiichi Sankyo Co Ltd
TSE:4568
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 850
6 148
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Daiichi Sankyo Co Ltd
Daiichi Sankyo Co Ltd
Investor Relations
Daiichi Sankyo Co., Ltd., a cornerstone of Japan's pharmaceutical industry, embarked on its journey in 2005 from the merger of two storied companies, Daiichi Pharmaceutical and Sankyo Co., both with roots stretching back to the early 20th century. They combined their rich histories and expertise to form a global powerhouse in healthcare. Daiichi Sankyo has since developed a compelling narrative in creating innovative pharmaceuticals, with a particular focus on oncology, managing cardiovascular risks, and tackling inflammatory diseases. This dedication is reflected in its flagship product, Enhertu (trastuzumab deruxtecan), a cutting-edge therapy in the field of oncology that has gained considerable global traction and approval for treating HER2-positive cancers. Constantly investing in research and development, the company aims to enhance its portfolio through innovative drugs that fulfill unmet medical needs, thereby driving sustainable growth.
The financial engine propelling Daiichi Sankyo forward is fueled by its robust product pipeline and strategic partnerships, such as its collaboration with AstraZeneca. These alliances not only bolster its research capabilities but also extend its market reach, especially in regions where regulatory landscapes can be intricate. While its revenue streams are primarily generated from pharmaceuticals, the company also invests in over-the-counter medications and vaccines, contributing to a diversified revenue base. Daiichi Sankyo’s strategy of maintaining a balanced portfolio, combined with its strategic commitment to pioneering treatments in oncology, aligns with its broader vision of being a leader in the global pharmaceutical arena, translating their scientific discoveries into tangible health solutions worldwide.
Daiichi Sankyo Co., Ltd., a cornerstone of Japan's pharmaceutical industry, embarked on its journey in 2005 from the merger of two storied companies, Daiichi Pharmaceutical and Sankyo Co., both with roots stretching back to the early 20th century. They combined their rich histories and expertise to form a global powerhouse in healthcare. Daiichi Sankyo has since developed a compelling narrative in creating innovative pharmaceuticals, with a particular focus on oncology, managing cardiovascular risks, and tackling inflammatory diseases. This dedication is reflected in its flagship product, Enhertu (trastuzumab deruxtecan), a cutting-edge therapy in the field of oncology that has gained considerable global traction and approval for treating HER2-positive cancers. Constantly investing in research and development, the company aims to enhance its portfolio through innovative drugs that fulfill unmet medical needs, thereby driving sustainable growth.
The financial engine propelling Daiichi Sankyo forward is fueled by its robust product pipeline and strategic partnerships, such as its collaboration with AstraZeneca. These alliances not only bolster its research capabilities but also extend its market reach, especially in regions where regulatory landscapes can be intricate. While its revenue streams are primarily generated from pharmaceuticals, the company also invests in over-the-counter medications and vaccines, contributing to a diversified revenue base. Daiichi Sankyo’s strategy of maintaining a balanced portfolio, combined with its strategic commitment to pioneering treatments in oncology, aligns with its broader vision of being a leader in the global pharmaceutical arena, translating their scientific discoveries into tangible health solutions worldwide.
Earnings Calls
Management
Sunao Manabe, D.V.M., Ph.D., is a prominent figure associated with Daiichi Sankyo Co., Ltd., a leading global pharmaceutical company headquartered in Japan. As a seasoned professional with extensive expertise in veterinary medicine and a doctorate in a related field, Dr. Manabe has significantly contributed to the advancement of innovative pharmaceutical products. At Daiichi Sankyo, Dr. Manabe has held various leadership roles, where he has been instrumental in overseeing research and development efforts, particularly focusing on drug discovery and development processes that align with the company's strategic goals. His background in veterinary medicine uniquely positions him to offer valuable insights into translational medicine and comparative models, enhancing the company's ability to develop effective therapeutic solutions. Dr. Manabe is known for his commitment to fostering innovation through scientific collaboration and has contributed to numerous initiatives that aim to address unmet medical needs. His work emphasizes the importance of integrating scientific research with practical applications to improve patient outcomes globally. Overall, Dr. Sunao Manabe's contributions to Daiichi Sankyo and the broader scientific community underscore his dedication to advancing healthcare through rigorous research and leadership in pharmaceutical development.
At Daiichi Sankyo, Dr. Manabe has held various leadership roles, where he has been instrumental in overseeing research and development efforts, particularly focusing on drug discovery and development processes that align with the company's strategic goals. His background in veterinary medicine uniquely positions him to offer valuable insights into translational medicine and comparative models, enhancing the company's ability to develop effective therapeutic solutions.
Dr. Manabe is known for his commitment to fostering innovation through scientific collaboration and has contributed to numerous initiatives that aim to address unmet medical needs. His work emphasizes the importance of integrating scientific research with practical applications to improve patient outcomes globally.
Overall, Dr. Sunao Manabe's contributions to Daiichi Sankyo and the broader scientific community underscore his dedication to advancing healthcare through rigorous research and leadership in pharmaceutical development.
Hiroyuki Okuzawa is a notable executive at Daiichi Sankyo Co., Ltd., a global pharmaceutical company based in Japan. As a high-ranking officer within the organization, Okuzawa has significantly contributed to the company's strategic and operational initiatives, leveraging his expertise in the pharmaceutical industry. He plays a crucial role in steering the company's global strategies, focusing on innovative research and development to enhance their competitive edge in the market. His leadership is instrumental in driving the company's mission of creating new pharmaceuticals to improve patient outcomes worldwide. His work often involves collaborations across various sectors within the company, ensuring the delivery of effective healthcare solutions and the successful execution of corporate goals.
Takashi Fukuoka, D.V.M., Ph.D., is a prominent figure in the pharmaceutical industry, particularly known for his role at Daiichi Sankyo Co., Ltd., a leading global pharmaceutical company based in Japan. With a strong background in veterinary medicine and a Ph.D., Dr. Fukuoka has contributed significantly to the field through his extensive research and leadership. At Daiichi Sankyo, Dr. Fukuoka has held various important positions that have leveraged his expertise in drug discovery and development. He plays a crucial role in advancing the company's research and development efforts, leading teams focused on creating new medical therapies and solutions. His work is vital in ensuring that Daiichi Sankyo remains at the forefront of pharmacological innovation, addressing unmet medical needs across various therapeutic areas. Dr. Fukuoka's contributions extend beyond his technical expertise, as he is also involved in strategic planning and decision-making processes within the company. His efforts help guide Daiichi Sankyo's mission to deliver innovative pharmaceuticals that improve patient health and quality of life globally.
At Daiichi Sankyo, Dr. Fukuoka has held various important positions that have leveraged his expertise in drug discovery and development. He plays a crucial role in advancing the company's research and development efforts, leading teams focused on creating new medical therapies and solutions. His work is vital in ensuring that Daiichi Sankyo remains at the forefront of pharmacological innovation, addressing unmet medical needs across various therapeutic areas.
Dr. Fukuoka's contributions extend beyond his technical expertise, as he is also involved in strategic planning and decision-making processes within the company. His efforts help guide Daiichi Sankyo's mission to deliver innovative pharmaceuticals that improve patient health and quality of life globally.
Dr. Shoji Hirashima is a respected figure in the pharmaceutical industry, particularly known for his contributions to Daiichi Sankyo Co., Ltd., a leading global pharmaceutical company based in Japan. Daiichi Sankyo is renowned for its focus on innovative research and development, particularly in the areas of oncology, cardiovascular diseases, and vaccines. Dr. Hirashima has played a key role in the company's research and development initiatives, often focusing on integrating scientific expertise and innovative approaches to create impactful medical solutions. His work involves overseeing clinical development, addressing unmet medical needs, and contributing to Daiichi Sankyo's strategic goals in delivering transformative therapies. His contributions extend to collaborations with academic institutions and other pharmaceutical entities, aiming to foster advancements in medical treatments and improve patient outcomes globally. As a leader within Daiichi Sankyo, Dr. Hirashima is instrumental in guiding both the scientific and operational aspects of the company's R&D endeavors. His work continues to influence the future direction of the pharmaceutical industry.
Dr. Hirashima has played a key role in the company's research and development initiatives, often focusing on integrating scientific expertise and innovative approaches to create impactful medical solutions. His work involves overseeing clinical development, addressing unmet medical needs, and contributing to Daiichi Sankyo's strategic goals in delivering transformative therapies.
His contributions extend to collaborations with academic institutions and other pharmaceutical entities, aiming to foster advancements in medical treatments and improve patient outcomes globally. As a leader within Daiichi Sankyo, Dr. Hirashima is instrumental in guiding both the scientific and operational aspects of the company's R&D endeavors. His work continues to influence the future direction of the pharmaceutical industry.
Koji Ogawa is a notable executive associated with Daiichi Sankyo Co., Ltd., a prominent global pharmaceutical company headquartered in Tokyo, Japan. As an executive leader, Ogawa has played a significant role in shaping the strategic direction and operational success of the company. Daiichi Sankyo is renowned for its innovative approach to healthcare, focusing on the research and development of novel therapies and pharmaceuticals to address unmet medical needs. While detailed personal information on Koji Ogawa, such as his educational background and prior career achievements, might be limited, his contributions to Daiichi Sankyo are part of the company's continued efforts in areas like oncology, cardiovascular medicine, and vaccine development. The company is committed to providing innovative and life-changing treatments, with executives like Ogawa involved in managing its expansive global operations and ensuring the company's adherence to its mission and values. In his role, Mr. Ogawa would typically be involved in high-level decision-making processes, corporate governance, and strategic partnerships, helping steer Daiichi Sankyo towards long-term growth and sustainability in the competitive pharmaceutical industry.
While detailed personal information on Koji Ogawa, such as his educational background and prior career achievements, might be limited, his contributions to Daiichi Sankyo are part of the company's continued efforts in areas like oncology, cardiovascular medicine, and vaccine development. The company is committed to providing innovative and life-changing treatments, with executives like Ogawa involved in managing its expansive global operations and ensuring the company's adherence to its mission and values.
In his role, Mr. Ogawa would typically be involved in high-level decision-making processes, corporate governance, and strategic partnerships, helping steer Daiichi Sankyo towards long-term growth and sustainability in the competitive pharmaceutical industry.
Tomohiro Kodama is an executive at Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Tokyo, Japan. As a member of the leadership team, Kodama has played a significant role in shaping the company's strategies and operations. Daiichi Sankyo is known for its research and development in the pharmaceutical industry, focusing on oncology, cardiovascular diseases, and other critical therapeutic areas. Kodama's work at Daiichi Sankyo involves overseeing strategic initiatives that align with the company's mission to enhance healthcare and improve the quality of life for patients worldwide. His contributions have been instrumental in advancing the company's pipeline of innovative drugs, particularly in oncology, where Daiichi Sankyo has made significant strides. With a commitment to innovation and excellence, Kodama and his team at Daiichi Sankyo continue to explore new opportunities to drive growth and deliver impactful healthcare solutions globally. His leadership and vision have helped maintain the company's reputation as a forward-thinking and socially responsible organization in the pharmaceutical sector.
Kodama's work at Daiichi Sankyo involves overseeing strategic initiatives that align with the company's mission to enhance healthcare and improve the quality of life for patients worldwide. His contributions have been instrumental in advancing the company's pipeline of innovative drugs, particularly in oncology, where Daiichi Sankyo has made significant strides.
With a commitment to innovation and excellence, Kodama and his team at Daiichi Sankyo continue to explore new opportunities to drive growth and deliver impactful healthcare solutions globally. His leadership and vision have helped maintain the company's reputation as a forward-thinking and socially responsible organization in the pharmaceutical sector.
Hiroto Kashiwase is an executive officer at Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Tokyo, Japan. He serves as an Executive Officer and is responsible for overseeing supply chain and manufacturing activities within the company. Kashiwase has played a significant role in ensuring the efficiency and reliability of Daiichi Sankyo's production and distribution networks. His work helps facilitate the company's mission to provide innovative and high-quality pharmaceutical products to improve patient care worldwide. Under his leadership, the company has strengthened its manufacturing capabilities and enhanced its supply chain strategies, contributing to its competitive position in the global market.
Naoto Tsukaguchi is the Executive Officer and Global Head of Corporate Communications at Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. In his role, Tsukaguchi is responsible for overseeing the company's communication strategies on a global scale, which includes managing its public relations, internal communications, and media outreach. He plays a key part in shaping the company's corporate image and ensuring consistent and effective messaging across all markets. With extensive experience in communication within the pharmaceutical industry, Tsukaguchi contributes significantly to enhancing the company's reputation and stakeholder engagement. His leadership is pivotal in maintaining transparency and promoting the innovations and developments Daiichi Sankyo brings to healthcare.
As of the latest available information, Kentaro Asakura is an executive officer at Daiichi Sankyo Co., Ltd., a global pharmaceutical company based in Japan. Daiichi Sankyo is known for its focus on innovative research and development in therapeutic areas such as oncology, cardiovascular medicine, and infectious diseases. Kentaro Asakura holds a significant role within the company, contributing to its strategic leadership and operational management. His responsibilities likely involve overseeing various aspects of the company's business operations and guiding its strategic direction to enhance global competitiveness and sustain growth in the pharmaceutical industry. Due to the company's commitment to medical innovation and patient care, Asakura's work would be pivotal in advancing Daiichi Sankyo's mission to address unmet medical needs and improve healthcare outcomes worldwide. His leadership is crucial in navigating the regulatory, commercial, and scientific challenges inherent in the pharmaceutical sector.
Kentaro Asakura holds a significant role within the company, contributing to its strategic leadership and operational management. His responsibilities likely involve overseeing various aspects of the company's business operations and guiding its strategic direction to enhance global competitiveness and sustain growth in the pharmaceutical industry.
Due to the company's commitment to medical innovation and patient care, Asakura's work would be pivotal in advancing Daiichi Sankyo's mission to address unmet medical needs and improve healthcare outcomes worldwide. His leadership is crucial in navigating the regulatory, commercial, and scientific challenges inherent in the pharmaceutical sector.
You don't have any saved screeners yet
